Smith & Nephew launches CARTIHEAL in Europe for Smith & Nephew stock investors
Published on 10/15/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSProduct rollout and financial markers
- CARTIHEAL became commercially available in Europe on October 6, 2026, initially across 12 countries.
- First-half 2026 revenue reached USD 3.10 billion and trading profit was USD 566.00 million.
- Smith & Nephew stock traded at EUR 12.75 at 12:51 p.m. CEST at Lang & Schwarz on October 15, 2026.
Smith & Nephew stock (ISIN GB0009223206) was trading at EUR 12.75 at Lang & Schwarz on October 15, 2026 at 12:51 p.m. CEST. On October 6, 2026, the medical technology company launched its CARTIHEAL AGILI-C cartilage repair implant commercially in Europe, according to GlobeNewswire.
CARTIHEAL reaches European markets
The implant is initially being introduced in Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Switzerland and the United Kingdom. Smith & Nephew said the product is designed to repair cartilage, restore bone and relieve pain, giving the launch a direct link to its orthopedic growth strategy.
The company entered the European rollout after introducing CARTIHEAL in the United States in 2024. Its investor materials identify Orthopaedics, Advanced Wound Management and Sports Medicine & ENT as its three business units.
What does the rollout mean for growth?
The product launch arrives as the latest reported figures show a mixed operating picture. In the first half of 2026, revenue rose 4.60 percent year over year to USD 3.10 billion, while trading profit increased 8.10 percent to USD 566.00 million, according to the company investor page.
That profit improvement came with a trading margin of 18.30 percent, compared with 17.70 percent in the first half of 2025. The company also expects second-half 2026 revenue growth of 5.00 percent to 5.50 percent, while its full-year revenue growth outlook is 4.00 percent.
Three dates frame the stock
On August 4, 2026, Smith & Nephew published second-quarter and first-half results with USD 3.10 billion of first-half revenue. On September 22, 2026, it announced FDA clearance and first surgical cases for the LANDMARK Total Knee System, with broader availability expected during 2027. On October 6, 2026, it launched CARTIHEAL AGILI-C in Europe across 12 countries, as GlobeNewswire reported.
Next reporting date
The next scheduled company date is November 4, 2026, when Smith & Nephew plans to release its third-quarter 2026 results, according to its investor-relations calendar.
Stock and investor perspective
The European rollout gives investors a concrete product milestone to track alongside execution in Orthopaedics and the company's margin program. The key test is whether new products can support revenue growth while trading profit continues to expand faster than sales.
The stock was trading at EUR 12.75 at Lang & Schwarz on October 15, 2026 at 12:51 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Smith and Nephew stock.
Smith & Nephew stock facts
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- Primary exchange: LSE
- Price Lang & Schwarz (as of October 15, 2026, 12:51 p.m. CEST): EUR 12.75
- Sector / Industry: Health care / Medical technology
- Index membership: FTSE 100
Market context: Market report FTSE 100.
